Clinical trial
A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast…
NCT00333775 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00333775 |
|---|---|
| Title | A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer |
| Official title | A Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Bevacizumab in Combination With Docetaxel in Comparison With Docetaxel Plus Placebo, as First Line Treatment for Patients With HER2 Negative Metastatic and Locally Recurrent Breast Cancer. |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Placebo to bevacizumab, Bevacizumab |
| Enrollment | 736 |
| Start date | Mar 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2013 |
| First posted | Jun 6, 2006 |
| Last update posted | Jan 27, 2016 |
| Countries | Australia, Austria, Belgium, Brazil, Canada, China, France, Germany, Italy, Lithuania, Mexico, Netherlands and 12 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: